Top Markets
Coin of the day
CARGO Therapeutics, Inc. Common Stock CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock

CRGX
Rang in Aktien #18091
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company... CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
Aktienkurs
$4.47
Zuletzt synchronisiert: 2025-08-20
Marktkapitalisierung
$213.06M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel CARGO Therapeutics, Inc. Common Stock (CRGX)

Kategorie

Dividendenrendite-Verlauf für CARGO Therapeutics, Inc. Common Stock (CRGX)
Dividendenrendite (TTM) von CARGO Therapeutics, Inc. Common Stock (Aktienkürzel: CRGX) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für CARGO Therapeutics, Inc. Common Stock (CRGX) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
2.48%
AU
0.00%
CH